About Arylacetamide deacetylase
Arylacetamide deacetylase (AADAC) is a protein
from Homo sapiens identified by UniProt accession
P22760, 399 residues long.
MolForge cross-references it against 0 known binders and
73 disease associations.
Target properties
| Protein name | Arylacetamide deacetylase |
|---|
| UniProt accession | P22760 |
|---|
| Gene | AADAC |
|---|
| Organism | Homo sapiens |
|---|
| Length | 399 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (73)
Diseases linked to this target (Open Targets).
- glioblastoma multiforme · score 0.16
- vital capacity · score 0.15
- hair shape measurement · score 0.14
- neurofibrillary tangles measurement · score 0.10
- androgenetic alopecia · score 0.08
- balding measurement · score 0.06
- Crohn's disease · score 0.06
- PHF-tau measurement · score 0.06
- alopecia · score 0.06
- colorectal cancer · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P22760-F1 | alphafold | PREDICTED | 95.63 | — |
Amino-acid sequence (399 residues)
MGRKSLYLLI VGILIAYYIY TPLPDNVEEP WRMMWINAHL KTIQNLATFV ELLGLHHFMD SFKVVGSFDE VPPTSDENVT VTETKFNNIL VRVYVPKRKS EALRRGLFYI HGGGWCVGSA ALSGYDLLSR WTADRLDAVV VSTNYRLAPK YHFPIQFEDV YNALRWFLRK KVLAKYGVNP ERIGISGDSA GGNLAAAVTQ QLLDDPDVKI KLKIQSLIYP ALQPLDVDLP SYQENSNFLF LSKSLMVRFW SEYFTTDRSL EKAMLSRQHV PVESSHLFKF VNWSSLLPER FIKGHVYNNP NYGSSELAKK YPGFLDVRAA PLLADDNKLR GLPLTYVITC QYDLLRDDGL MYVTRLRNTG VQVTHNHVED GFHGAFSFLG LKISHRLINQ YIEWLKENL
Explore Arylacetamide deacetylase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets